Uncategorized

After Missing Kezar Buyout in 2024, Tang Returns as CEO of Aurinia With $50M Offer

Published

1 week ago

on

Serial biotech investor Kevin Tang previously unsuccessfully tried to buy Kezar Life Sciences via Concentra Biosciences, a biotech consolidation company owned by the venture capital firm he runs.

Related Topics:

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version